한글목차

지질 조절제 세계 시장 규모는 2024년 72억 1,000만 달러로 2030년에는 98억 4,000만 달러에 달할 것으로 예상되며, 예측 기간 동안 연평균 5.32%의 CAGR로 성장할 것으로 예상됩니다.

이 시장은 심혈관질환과 당뇨병의 전 세계 발병률 증가, 인구 고령화, 콜레스테롤 관리에 대한 인식 증가 등을 배경으로 꾸준한 성장세를 보이고 있습니다. 기술 혁신, 특히 신경 및 치료법의 발전, 정부 및 민간 부문의 투자 확대는 시장 확대에 유리한 여건을 조성하고 있습니다. 노년층은 만성질환에 걸리기 쉬우며, 이상지질혈증 관리 및 합병증 예방에 필수적인 지질 조절제의 수요는 증가할 것으로 예상되며, 예방적 심혈관 치료의 중요성이 커지고 있습니다.

시장 촉진요인

심혈관질환의 유병률 증가

주요 시장 과제

높은 개발 비용

주요 시장 동향

바이오의약품의 부상

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 세계의 지질 조절제 시장 전망

• 시장 규모 및 예측
  • 금액별
• 시장 점유율과 예측
  • 유형별{스타틴(브랜드 스타틴, 스타틴 배합제, 제네릭 스타틴), 비스타틴(피브린산 유도체, 담즙산 흡착제, 니코틴산 유도체, 기타 신제품)}
  • 지역별
  • 기업별(2024년)
• 시장 맵

제6장 북미의 지질 조절제 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 미국
  • 캐나다
  • 멕시코

제7장 유럽의 지질 조절제 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 독일
  • 영국
  • 이탈리아
  • 프랑스
  • 스페인

제8장 아시아태평양의 지질 조절제 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 일본
  • 한국
  • 호주

제9장 남미의 지질 조절제 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 지질 조절제 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 최근 동향
• 인수합병

제13장 세계의 지질 조절제 시장 : SWOT 분석

제14장 Porter's Five Forces 분석

• 업계내 경쟁
• 신규 참여의 가능성
• 공급업체의 능력
• 고객의 능력
• 대체 치료법 위협

제15장 경쟁 구도

• AbbVie Inc
• Amgen Inc.
• Andrx Corp
• AstraZeneca PLC
• Bristol-Myers Squibb Co
• Merck KGaA
• Novartis AG
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd
• Dr. Reddy's Laboratories Ltd.

제16장 전략적 제안

제17장 조사 회사 소개 및 면책사항

영문목차

The Global Lipid Regulators Market was valued at USD 7.21 billion in 2024 and is projected to reach USD 9.84 billion by 2030, growing at a CAGR of 5.32% during the forecast period. The market is experiencing steady growth driven by a rising global incidence of cardiovascular diseases and diabetes, an aging population, and increasing awareness of cholesterol management. Technological innovations, particularly in neural and therapeutic advancements, as well as increased government and private sector investments, are creating favorable conditions for market expansion. With the elderly being more vulnerable to chronic illnesses, the demand for lipid regulators-essential in managing dyslipidemia and preventing complications-is anticipated to increase, reinforcing their importance in preventive cardiovascular care.

Key Market Drivers

Rising Prevalence of Cardiovascular Diseases

The global surge in cardiovascular diseases (CVDs) serves as a key catalyst for the lipid regulators market. CVDs, including coronary artery disease, stroke, and hypertension, are a leading cause of death globally. According to the World Health Organization, CVDs account for nearly 32% of all deaths worldwide. Dyslipidemia, characterized by abnormal cholesterol or triglyceride levels, is a primary risk factor in the development of CVDs. Lipid regulators, particularly statins and other lipid-lowering agents, are vital in controlling cholesterol levels, reducing disease progression, and improving patient outcomes. With a growing global focus on preventive healthcare, the demand for lipid-regulating therapies continues to rise, offering growth opportunities for pharmaceutical companies and healthcare providers.

Key Market Challenges

High Development Costs

High development costs remain a major challenge in the lipid regulators market. The process of discovering, developing, and commercializing new lipid-lowering drugs involves extensive R&D, clinical trials, and regulatory approvals, all of which require substantial financial investment. Preclinical and clinical research phases are time-consuming and expensive, involving the recruitment of skilled professionals and maintenance of specialized facilities. Additionally, ensuring safety and efficacy through compliance with stringent regulatory frameworks adds further financial burden. These cost-related barriers particularly affect smaller pharmaceutical firms, potentially limiting innovation and delaying market entry of newer lipid-regulating products.

Key Market Trends

Rise of Biopharmaceuticals

Biopharmaceuticals are reshaping the lipid regulators market by enabling more targeted, effective treatment options. Unlike traditional chemical-based drugs, biopharmaceuticals-such as monoclonal antibodies and recombinant proteins-interact with specific biological pathways to regulate lipid metabolism. These advanced therapies offer improved safety profiles and enhanced therapeutic outcomes, particularly for patients who are unresponsive to conventional statins. The advancement of technologies like gene editing and synthetic biology is accelerating the development of biologics. While the infrastructure and expertise required for biopharmaceutical development present initial investment challenges, the long-term benefits-such as premium pricing and extended patent exclusivity-make them a lucrative segment within the lipid regulators market.

Key Market Players

• AbbVie Inc
• Amgen Inc.
• Andrx Corp
• AstraZeneca PLC
• Bristol-Myers Squibb Co
• Merck KGaA
• Novartis AG
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd
• Dr. Reddy's Laboratories Ltd.

Report Scope:

In this report, the Lipid Regulators Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Lipid Regulators Market, By Type:

• Statins (Branded statins, Statin combinations, and Generic statins)
• Non-statins (Fibric-acid derivatives, Bile-acid Sequestrants, Nicotinic Acid Derivatives, and Other New Products)

Lipid Regulators Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • Germany
  • United Kingdom
  • Italy
  • France
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Lipid Regulators Market.

Available Customizations:

Lipid Regulators Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Lipid Regulators Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type {Statins (Branded statins, Statin combinations, and Generic statins), and Non-statins (Fibric-acid derivatives, Bile-acid Sequestrants, Nicotinic Acid Derivatives, and Other New Products)}
  • 5.2.2. By Region
  • 5.2.3. By Company (2024)
• 5.3. Market Map

6. North America Lipid Regulators Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Lipid Regulators Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
  • 6.3.2. Canada Lipid Regulators Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
  • 6.3.3. Mexico Lipid Regulators Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type

7. Europe Lipid Regulators Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Lipid Regulators Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
  • 7.3.2. United Kingdom Lipid Regulators Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
  • 7.3.3. Italy Lipid Regulators Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecasty
      • 7.3.3.2.1. By Type
  • 7.3.4. France Lipid Regulators Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
  • 7.3.5. Spain Lipid Regulators Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type

8. Asia-Pacific Lipid Regulators Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Lipid Regulators Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
  • 8.3.2. India Lipid Regulators Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
  • 8.3.3. Japan Lipid Regulators Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
  • 8.3.4. South Korea Lipid Regulators Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
  • 8.3.5. Australia Lipid Regulators Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type

9. South America Lipid Regulators Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Lipid Regulators Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
  • 9.3.2. Argentina Lipid Regulators Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
  • 9.3.3. Colombia Lipid Regulators Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type

10. Middle East and Africa Lipid Regulators Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Lipid Regulators Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
  • 10.3.2. Saudi Arabia Lipid Regulators Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
  • 10.3.3. UAE Lipid Regulators Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions

13. Global Lipid Regulators Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Treatment Types

15. Competitive Landscape

• 15.1. AbbVie Inc
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Amgen Inc.
• 15.3. Andrx Corp
• 15.4. AstraZeneca PLC
• 15.5. Bristol-Myers Squibb Co
• 15.6. Merck KGaA
• 15.7. Novartis AG
• 15.8. Pfizer Inc.
• 15.9. Teva Pharmaceutical Industries Ltd
• 15.10. Dr. Reddy's Laboratories Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer